Results 81 to 90 of about 102,854 (205)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

Biomarker Research, 2017
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon 9 ...
Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K. Hayward, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos   +11 more
doaj   +1 more source

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

eJHaem, 2020
Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep‐sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients.
Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, Bastien Jamet, Céline Bossard, Benoit Tessoulin, Thomas Gastinne, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Chloé Antier, Olivier Theisen, Françoise Kraeber‐Bodéré, Steven Le Gouill, Marie C. Béné, Philippe Moreau, Cyrille Touzeau   +16 more
doaj   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source

Inhibition of Mutated BRAF in Melanoma

New England Journal of Medicine, 2010
To the Editor: In their phase 1 trial, Flaherty and colleagues (Aug. 26 issue)1 report that treatment with a BRAF inhibitor was effective for the majority of patients with metastatic melanomas carrying the BRAF V600E mutation. Despite encouraging results, tumor resistance to the drug came into question, possibly as a result of transactivation of other ...
Taegyun, Kim, Jihyun, Kim, Min-Geol, Lee
openaire   +3 more sources

Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma

Indian Journal of Endocrinology and Metabolism, 2017
Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in high frequencies associated with papillary thyroid cancer (PTC). The phenotype of these cancers expressed aggressive clinical and pathological features. The
C Gopalakrishnan Nair, Misha Babu, Lalitha Biswas, Pradeep Jacob, Riju Menon, A K Revathy, Krishnanunni Nair   +6 more
doaj   +1 more source

MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. [PDF]

, 2016
BackgroundResection of colorectal liver metastasis (CRLM) can be curative. Predicting which patients may benefit from resection, however, remains challenging. Some microRNAs (miRNAs) become deregulated in cancers and contribute to cancer progression.
D'Angelica, Michael I, Goodarzi, Hani, Jarnagin, William R, Kingham, T Peter, Konstantinidis, Ioannis T, Kuk, Deborah, Nguyen, Hoang CB, Sadot, Eran, Saltz, Leonard, Shia, Jinru, Tavazoie, Sohail F, Zhang, Steven, Zheng, Jian   +12 more
core   +1 more source

The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]

, 2020
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J, Kato, Shumei, Kurzrock, Razelle, Lippman, Scott M   +3 more
core  

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

, 2017
An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant ...
Chmielowski, Bartosz, Dry, Sarah M, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Tan, Yuying, Unno, Michiaki   +15 more
core   +2 more sources

BRAF mutation: supporting diversity in HCL [PDF]

Blood, 2012
In this issue of Blood, Xi and colleagues report on v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in hairy cell leukemia (HCL) subsets, demonstrating that BRAF V600E mutations are absent in variant HCL forms and in a subset of classic HCL (HCLc).
openaire   +2 more sources

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Oncotarget, 2014
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop
SPAGNOLO, FRANCESCO, GHIORZO, PAOLA, Queirolo, P.   +2 more
openaire   +3 more sources